placebo effects – clinical data
Post on 19-Oct-2014
23 views
DESCRIPTION
Presentation from the International Congress of the Royal College of Psychiatrists 24-27 June 2014, LondonTRANSCRIPT
![Page 1: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/1.jpg)
John M. Kelley, PhD
Associate Professor, Endicott College
Deputy Director, Program in Placebo Studies, Harvard Medical School
Staff Psychologist, Massachusetts General Hospital
Placebo Effects – Clinical Data
![Page 2: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/2.jpg)
Overview of Goals
1. Demonstrate that the placebo effect is powerful
2. Show that the placebo effect can be decomposed
into separate factors
3. Show that these placebo effects are active not only
when placebos are administered but also when
active treatments are delivered.
4. Describe a method by which placebo effects might
be harnessed in medical and psychiatric treatments
![Page 3: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/3.jpg)
Beecher (1955). JAMA, 59, 1602-1606
![Page 4: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/4.jpg)
Hrobjartsson (2014). NEJM, 344(21), 1594-1602
![Page 5: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/5.jpg)
Components of the Placebo Response
• Regression to the mean
• Natural history of the disorder
• Change in life circumstances (diet, exercise,
social support, stress reduction, rest)
• Other psychological or physical treatments
• Placebo effect
![Page 6: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/6.jpg)
Kaptchuk (2008). BMJ, 336, 998-1003.
![Page 7: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/7.jpg)
Placebo Acupuncture Needle
![Page 8: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/8.jpg)
Placebo Acupuncture Needle
Needle Set Up Placebo Needle Genuine Needle
Streitberger (1998). The Lancet, 352, 354-365.
![Page 9: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/9.jpg)
Design
• 262 patients with IBS
• Randomized to 3 treatment groups:
(1) Waitlist control (N=87)
(2) Limited placebo acupuncture (N=88)
(3) Augmented placebo acupuncture (N=87)
• 3-week trial, 2 treatments per week
![Page 10: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/10.jpg)
Outcomes at 3-week end point
©2008 by British Medical Journal Publishing Group
![Page 11: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/11.jpg)
Kam-Hansen (2014). Science Translational Medicine, 6, 218ra215
![Page 12: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/12.jpg)
Treatment Conditions
• Within-subjects experiment in 66 migraine patients
• 7 migraines attacks treated in random order as follows:
• No Treatment
• Told Placebo, Given Placebo
• Told Uncertain, Given Placebo
• Told Drug, Given Placebo (deception)
• Told Placebo, Given Drug (deception)
• Told Uncertain, Given Drug
• Told Drug, Given Drug
![Page 13: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/13.jpg)
3 x 2 Design
Two factors crossed with each other:
Labeling (expectancy)
- “Placebo”
- “Drug or Placebo”
- “Drug”
Pill Type
- Active Drug (Maxalt)
- Inactive Placebo
![Page 14: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/14.jpg)
![Page 15: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/15.jpg)
First Proposal for Open-Label Placebo
Walter Brown, MD:
“Among less severely depressed patients … the placebo
response rate is close to 50% and often indistinguishable
from the response rate to antidepressants … I propose that
the initial treatment for selected depressed patients should
be four to six weeks of placebo. Patients so treated should
be informed that the placebo pill contains no drug but that
this treatment can be helpful.”
Brown (1994). Neuropsychopharmacology, 10(4), 265-269.
![Page 16: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/16.jpg)
Rationale for Placebo Efficacy
Clinicians explained that placebos are inactive substances like a
sugar pill, which contain no medication. They also noted that:
(1) In RCTs, placebo response often rivals response to active
treatment;
(2) Classical conditioning is a possible mechanism for
automatic self-healing;
(3) Placebo-treated patients who are more compliant have
better outcomes; and
(4) Positive expectations increase placebo effects, but it is OK
to have doubts.
Clinicians delivered the rationale in a natural and supportive
manner that allowed for questions and answers.
![Page 17: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/17.jpg)
Kaptchuk (2010). PLOS ONE, 5(12), e15591
![Page 18: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/18.jpg)
Design
• 3-week trial of open-label placebo in 80 IBS patients
• Prior to randomization all patients were given a rationale for
why placebos might be effective :
(1) The placebo effect is powerful in RCTs
(2) The body can automatically respond to placebos
(3) A positive attitude is helpful but not essential
(4) Taking the pills faithfully is essential
• Patients were randomly assigned to either:
(1) Open-Label Placebo Pill, twice daily (N=43)
(2) No Treatment Control (N=37)
![Page 19: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/19.jpg)
![Page 20: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/20.jpg)
Kelley (2012). Psychotherapy and Psychosomatics, 81:312–314
![Page 21: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/21.jpg)
Design
• 20 MDD patients recruited for a 4-week trial
• Prior to randomization all patients were given the persuasive
rationale for why placebos might work that included
(1) The placebo effect is powerful
(2) The body can automatically respond to placebos
(3) A positive attitude is helpful but not essential
(4) Taking the pills faithfully is essential
• Patients were randomly assigned to either:
(1) Open-Label Placebo Pill, twice daily (N=11) for 4 weeks
(2) Waitlist Control (N=9) for 2weeks, followed by 4 weeks
of Open-Label Placebo
![Page 22: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/22.jpg)
Improvement by Group at 2 Weeks
Measure Waitlist Open-Label d p
HamD-17 -0.67±4.00 1.64±4.52 .54 .26
QIDS -0.22±2.44 2.27±3.88 .77 .13
SDQ 1.38±10.77 3.70±18.98 .15 .75
Note: All values are means ± SD. Positive scores indicate
improvement.
![Page 23: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/23.jpg)
Ham-D-17 Improvement at 2 Weeks
-1
0
1
2
Waitlist
Control
Open
Placebo
![Page 24: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/24.jpg)
Improvement after 4 Weeks of Placebo
Note: All values are means ± SD. Positive scores indicate
improvement.
Measure Pre Post Change d p
HamD-17 18.00±4.94 14.75±6.61 3.25±6.01 .57 .03
QIDS 14.85±2.68 12.10±4.34 2.75±3.84 .76 .005
SDQ 146.94±19.71 138.75±27.65 9.89±15.71 .34 .02
![Page 25: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/25.jpg)
Pre-Post Ham-D Scores (N=20)
18.0
14.8
0
2
4
6
8
10
12
14
16
18
20
Baseline 4 Weeks
![Page 26: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/26.jpg)
Criticisms of Open-Label Placebo
• Are we testing open-label placebo or are we testing the
rationale?
• Isn’t generalization limited to patients who are willing to take
open-label placebos?
![Page 27: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/27.jpg)
Where do we go from here?
• Larger 2-arm trial of open-label placebos vs. waitlist
control
• 3-Arm trial
• Waitlist control
• Open-Label Placebo
• Open-Label Drug
![Page 28: Placebo effects – clinical data](https://reader034.vdocument.in/reader034/viewer/2022051608/5443f37bb1af9f640a8b46f4/html5/thumbnails/28.jpg)
Thank you for your attention!
My Principal Collaborators
• Ted Kaptchuk
• Irving Kirsch
• Tony Lembo
• Maurizio Fava
• Rami Burstein